Now dermatologists are increasingly prescribing the drug Rogaine, known generically as minoxidil, in low-dose pills to help ...
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Apple’s App Store trend of the year was self-care back in 2018—its growth is accelerating, and not just in the most popular ...
Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...
The latest trend in treating hair loss may sound familiar — essentially, it’s a repurposed drug first popularized in the ...
A growing number of young men worried about hair loss are running into serious health trouble after—legally—buying the drug ...
Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.
Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...
Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.
Whales with a lot of money to spend have taken a noticeably bullish stance on Hims & Hers Health. Looking at options history for Hims & Hers Health (NYSE:HIMS) we detected 16 trades. If we ...